CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced that the presentation of data from the luspatercept phase 2 clinical trial in patients with lower risk myelodysplastic syndromes (MDS) was selected for “Best of ASH” at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition. The “Best of ASH” session, led by the 2014 Annual Meeting Scientific Program Co-Chairs, highlighted twenty-four of the top hematology breakthroughs selected from the meeting’s more than 4,000 abstract presentations.
Help employers find you! Check out all the jobs and post your resume.
